Back to Our Insights
Driving the next wave of innovation in CAR T-cell therapies

McKinsey insights on cell and gene therapy

Continuing advances in cell and gene therapy (CGT) are transforming how biopharma companies treat and potentially cure certain diseases. Browse our collection of articles for an in-depth look at the opportunities, challenges, and implications for stakeholders in this fast-evolving field, and explore how McKinsey’s new Digital Capability Center for Cell and Gene Therapy will help biopharma companies accelerate digital transformations in manufacturing and the journey to operational excellence. Contact us to learn more.

Our insights

Article

How AI can accelerate R&D for cell and gene therapies
– Cell and gene therapies show significant promise but need substantial innovation to unlock full potential for patients. Scaling digital and analytics in discovery and R&D is part of the solution.
Article

Eight imperatives for launching cell and gene therapies
– Companies launching new cell and gene therapies can live up to their promise of transforming patient lives through proper preparation of the market, their products, and internal go-to-market models.
Article

Viral-vector therapies at scale: Today’s challenges and future opportunities
– Viral-vector gene therapies are here to stay. Keeping pace with increasing demand requires consideration of challenges, the potential for standardization, and strategizing for accelerating patient access.
Video

How could gene therapy change healthcare in the next ten years?
– Cell and gene therapies are at the forefront of innovation and transforming how we treat and potentially cure certain diseases. What will the next decade hold for these life-changing therapies?
Article

Gene-therapy innovation: Unlocking the promise of viral vectors
– Viral-vector gene therapies show great promise, but the full extent of their clinical impact in the long term is not yet certain. Success depends on innovative solutions that remain under development.
Article

A call to action: Opportunities and challenges for CGTs in Europe
– The speed at which scientific breakthroughs in cell and gene therapy translate into advances in European healthcare could depend on how quickly stakeholders address some uniquely European challenges.
Article

Delivering innovation: 2020 oncology market outlook
– At the dawn of a new decade, we take stock of advances and unmet needs in the oncology pharmaceutical market. What will it take to deliver innovation to patients over the next ten years?
Article

Managing China’s growing oncology burden
– Significant increases in incidence rates have made cancer a high priority in China. Progress has resulted from innovative treatments and greater access to care, yet much more needs to be done.
Article

COVID-19 and cell and gene therapy: How to keep innovation on track
– Cell and gene therapies promise life-changing treatments, but the pandemic has hit the sector hard. A survey reveals the extent of the disruption and suggests actions to help companies become more resilient.
Article - McKinsey Global Institute

Ten innovations that can improve global health
– By 2040, new technologies could reduce the total burden of disease by 6 to 10 percent.
Article

Biopharma portfolio strategy in the era of cell and gene therapy
– Many biopharma companies are investing in cell and gene therapy, albeit cautiously, amid a nascent market. Understanding investment opportunities and entry strategies will help guide their portfolio decisions.
Article

Driving the next wave of innovation in CAR T-cell therapies
– Unlocking the full potential of CAR T-cell therapies requires investment in four areas.
Article

Gene therapy coming of age: Opportunities and challenges to getting ahead
– Amid breakthroughs in gene editing, the pharma industry must recalibrate its development and reimbursement model for therapies that go beyond the traditional approach to disease treatment.
Article

An engineering approach to derisking R&D for novel drug modalities
– Borrowing from the field of engineering, applying a “failure modes analysis” can quickly take some unnecessary risk out of a development program for innovative modalities.

Featured capability

New McKinsey center to help transform and digitally enable cell- and gene-therapy manufacturing

McKinsey Digital Capability Center for Cell and Gene Therapy joins McKinsey’s fast-growing global network of Digital Capability Centers—immersive learning environments that inspire and equip organizations in achieving digital-enabled transformations and operational excellence.
Read more

Featured experts

Lieven Van der Veken
Senior Partner, Lyon
Draws on his professional background in neuroscience to help pharmaceutical companies and public health organizations with challenges in strategy, growth, innovation, leadership, and change
Navjot Singh
Senior Partner, Boston
Works with Top Teams on what matters! Drives innovation at the intersection of science, engineering, medicine, business, and government. Combines expertise in strategy, operations, technology, transformations, risk, M&A and business development to support life sciences, healthcare, higher education, technology, semiconductors, private equity/venture capital and government clients.